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Secondary adrenal insufficiency (SAI) is a potentially life-threatening endocrine disorder
due to an impairment of corticotropin (ACTH) secretion from any process affecting
the hypothalamus or pituitary gland. ACTH deficit can be isolated or associated with
other pituitary failures (hypopituitarism). An increased mortality due to cardiovascular,
metabolic, and infectious diseases has been described in both primary and secondary
adrenal insufficiency. However, few studies have provided compelling evidences on the
underlying mechanism in SAI, because of the heterogeneity of the condition. Recently,
some studies suggested that inappropriate glucocorticoid (GCs) replacement therapy, as
for dose and/or timing of administration, may play a role. Hypertension, insulin resistance,
weight gain, visceral obesity, increased body mass index, metabolic syndrome, impaired
glucose tolerance, diabetes mellitus, dyslipidemia have all been associated with GC
excess. These conditions are particularly significant when SAI coexists with other
pituitary alterations, such as growth hormone deficiency, hypogonadism, and residual
tumor. Novel regimen schemes and GC preparations have been introduced to improve
compliance and better mimick endogenous cortisol rhythm. The controlled trials on the
improved replacement therapies, albeit in the short-term, show some beneficial effects
on cardiovascular risk, glucose metabolism, and quality of life. This review examines the
current evidence from the available clinical trials investigating the association between
different glucocorticoid replacement therapies (type, dose, frequency, and timing of
treatment) and glycometabolic alterations in SAI.
Keywords: secondary adrenal insufficiency, insulin resistance, weight gain, bodymass index,metabolic syndrome,
impaired glucose tolerance, diabetes mellitus, glucocorticoids
INTRODUCTION
Secondary adrenal insufficiency (SAI) is a rare potentially life-threatening condition due to
any disturbance involving the pituitary gland (space-occupying lesions, trauma or genetic
abnormalities) and interfering with corticotropin (ACTH) secretion (1).
The impairment of ACTH secretion can be isolated or can be associated with other defected
pituitary secretions (hypopituitarism) (1). Studies on outcomes in hypopituitary patients have
shown that the frequency of SAI is between 41 and 94% (2). SAI shows a prevalence of 150–280
per million with a higher prevalence in women (3).
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Moreover iatrogenic suppression of the hypothalamic–
pituitary–adrenal axis caused by long-term glucocorticoid
exposure should be carefully considered and patients taking
long-term oral, inhaled, intranasal, intra-articular, or topical
glucocorticoids, should be assessed for possible hypocortisolism
(4).
Several studies have demonstrated an increased mortality in
patients with cortisol deficiency attributable to cardiovascular,
metabolic, neoplastic and infective diseases (5). The incidence of
adrenal crises is increasing, at an estimated 3–6% per year among
SAI, with a dramatic 1% mortality rate (5).
On the basis of the Endocrine Society Clinical Practice
guidelines, themanagement of patients with adrenal insufficiency
(AI) consists in treatment with hydrocortisone (HC) or
cortisone acetate (CA), which are the most physiological
choice for glucocorticoid replacement. The recommended daily
hydrocortisone dose is 10–12 mg/m2 divided in two to three
doses, administering half to two thirds of the total daily dose
in the morning, generally suggesting lower daily dosage in SAI
(1, 6). However, optimal glucocorticoid replacement therapy for
adrenally insufficient patients is still controversial due to lack of
evidence from randomized trials.
One of the main concerns in the management of AI is
balancing the need to increase the usual glucocorticoid (GC) dose
during stress conditions. The goal is the prevention of adrenal
crises on one side, with the need to reduce over-exposure in
the uneventful daily life. Even when administered according to
current guidelines, multiple daily doses of glucocorticoids (md-
GC) have been associated with bone loss and reduced quality of
life (7, 8) probably from a higher time exposure in the evening (9).
Hypercortisolism is associated to hyperglycaemia and
insulin resistance (IR), increasing glicogenolisis, and hepatic
gluconeogenesis and playing a direct role on pancreatic insulin
secretion (10). Phosphatidylinositol-3 kinase pathway is involved
in insulin signaling reducing nitric oxide synthase activation
and causing endothelial impairment, ultimately increasing
cardiovascular risk (11). Hypertension, IR, weight gain, visceral
obesity, increased body mass index (BMI), metabolic syndrome,
impaired glucose tolerance, diabetes mellitus, dyslipidemia are
associated with GC excess or unphysiological GC replacement
in patients with SAI (12). All these complications are more
relevant when SAI coexists with other pituitary disorders,
such as neoplasms of the sellar region, growth hormone
deficiency (GHD), hypogonadism, and all the subsequent
comorbidities that commonly affect the hypopituitary patient
(2, 13).
A rare but interesting cause of SAI is the homozygous or
composed heterozygous loss-of-function mutations of POMC
gene, leading to early onset adrenal insufficiency, obesity, and
altered pigmentation (14). Given the pivotal role of POMC
in regulating appetite and metabolism, whether the lack of
POMC secretion in all-causes SAI can play a role in metabolic
complications has never been investigated and should prompt
further studies.
Recently, modified-release preparations have been developed
to mimic the physiological cortisol rhythm and improve
patients’ compliance (15, 16). The once-daily modified-release
hydrocortisone tablet (od-MRHC) has been introduced to
prevent the afternoon peaks given by conventional therapies
administered in multiple daily doses. Treatment with the od-
MRHC seems to improve cardiovascular risk factors, glucose
metabolism, and quality of life in controlled trials (17–
19).
The objective of this review is to evaluate the association
between inadequate glucocorticoid replacement therapy (type,
dose, frequency, and timing of treatment) and glycometabolic
alterations in SAI, on the basis of currently available data.
GLUCOCORTICOIDS AND GLUCOSE
HOMEOSTASIS
Glucocorticoids (GCs) are so named based on the results
of Houssay’s studies published in 1954, where it was
shown that they exert an important action on glucose
regulation (20) through intracellular glucocorticoid receptor
protein.
Polymorphisms of glucocorticoid receptor may influence the
peripheral activity of cortisol (21). In target tissues, the activation
and inactivation of GCs are regulated by the enzyme 11β-
hydroxysteroid dehydrogenase (22).
The GCs role on glucose homeostasis is due to the
impairment of various mechanisms including β cell alterations
(glucose sensitivity and insulin release) and IR, leading to a
reduction in glucose disposal and to an increased production
of endogenous glucose (10). Their ability to counterbalance
the insulin action and to increase glucose levels are a major
concern in patients with Cushing’s syndrome/disease or
under GCs treatment for immunomodulatory purposes
(23). Physiologically, the alterations in peripheral insulin
sensitivity is counterbalanced by increased β-cell function
(24–27). Insulin demand is increased by GCs, and when the
compensative insulin secretion is inadequate or compromised,
fasting and/or postprandial hyperglycaemia may occur
(10).
GCs interfere with the insulin receptor signaling cascade
affecting these processes, and glucose homeostasis is usually
maintained by β-cell compensations (10). Individuals with any
susceptibility to glucose homeostasis alterations, such as reduced
sensitivity to insulin (28), an impaired insulin response to
glucose (29), first degree relatives with type 2 diabetes (30),
obesity (31) and older age (32), are more prone to develop GCs
induced alterations. A possible mechanism is the inadequate β-
cells response. Hence, considering the negative effects of GCs
on glucose homeostasis, their clinical use should be limited,
especially in patients with risk factors for diabetes.
An interesting finding is that in the majority of in vivo studies,
GCs treatment also induces an increase in glucagon and amylin
plasma levels. Increased plasma amylin levels have been shown
to exert a diabetogenic effect due to the higher rates of toxic
amylin aggregation mediated by the islet amyloid polypeptide
(IAPP) (33). Additionally, hyperglucagonaemia could oppose
insulin actions and increase hepatic glucose output, a mechanism
described in diabetes (34).
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GC REPLACEMENT THERAPY IN SAI
Replacement therapy in SAI does not require the
mineralocorticoid administration because the renin-angiotensin-
aldosterone axis is preserved (35, 36), instead of in primary
adrenal insufficiency (PAI). Nevertheless, GCs replacement
therapy shows wide variability in the type, dose, frequency, and
timing of treatment (37).
However, there is general consent that replacement treatment
should aim to obtain the physiological daily dose and to simulate
the circadian cortisol rhythm.
Patients with SAI due to iatrogenic suppression of the
hypothalamic–pituitary–adrenal axis requires conventional
treatment and the same patient education as patients with central
hypocortisolism due to disturbance involving the pituitary gland
(4).
Hydrocortisone (HC), cortisone acetate (CA) and prednisone
are the most frequently used drugs (37) for replacement therapy.
HC and CA are usually administered with a higher dose in the
morning in the fasting state and one or two fractioned doses later
in the day (before 06:00 pm) (38). Compared to hydrocortisone,
prednisone and dexamethasone have greater glucocorticoid
activity (respectively 5 and 30- to 50-fold) and a longer half-life,
exposing the patients to a greater time-exposure, and the risk
of over-treatment (at the currently recommended doses), thus
explaining the cardio-metabolic complications observed in these
subjects (12, 39).
In patients with partial cortisol insufficiency, signs and
symptoms should be evaluated to decide if the starting dose can
be lower than conventional replacement doses (5–10 mg/day)
or to limit exogenous glucocorticoids intake to rescue treatment
when needed.
Considering a progressive worsening of the metabolic status
in hypopituitary patients receiving doses greater than 20 and
greater than 30 mg/day, the mean daily dose of hydrocortisone
prescribed should be lower than 30mg (40).
This is especially relevant in SAI, where many factors can
influence the daily requirement of glucocorticoids, such as
residual ACTH secretion, changes in binding proteins, other
concomitant hormone replacements and related comorbidities.
Considering that a residual ACTH secretion and HPA-axis
function may be present, lower glucocorticoid doses, especially
in the afternoon, might be sufficient to replace patients with SAI
when compared to PAI. Despite this, in clinical practice there is a
tendency to use the same doses of GCs in both SAI and PAI, given
at the same timing. It might be that in patients with SAI, even
those with a non-reversible deficit, the residual ACTH secretion
is sufficient to maintain the low levels that are physiologically
required and produced to cover the afternoon and evening.
The modified release preparations, and the continuous
infusions, has been developed to avoid the afternoon
administrations, causing multiples peaks at a time when
glucocorticoid sensitivity is higher, and thus replicate the shape
of a gradual cortisol decline during the day of adrenal sufficient
subject (15, 38). Although initially thought to treat PAI, this
advantage of the modified release preparation could well apply
to SAI.
GLYCOMETABOLIC EFFECTS OF GC
REPLACEMENT THERAPY
Dosing and Timing
Compared to the past, the current guidelines recommend lower
doses of HC to align with cortisol production rates of healthy
volunteers (41). In non-AI subjects, there is a correlation between
hypercortisolism and metabolic impairment, but in AI has yet to
be proven (42).
An open interventional study was conducted in 17 SAI
patients to evaluate the effect of increased dose of HC (or
equivalent) to 30 mg/d on cardiovascular system and the role
of insulin in the impairment of cardiovascular function. No
significant differences in fasting and post-glucose load pulse wave
velocities were observed on the higher glucocorticoid regimen.
This study showed that fasting augmentation index and reactive
hyperemia index were lower on the higher glucocorticoid dose
and post-glucose load changes were not significantly different.
The insulin sensitivity or secretion didn’t show alterations on the
higher glucocorticoid regimen (43).
Several studies have evaluated the effects on metabolism and
glucose homeostasis of reducing the daily dose of hydrocortisone
(Table 1).
Dunne FP et al. investigated the impact of the reduction of
daily HC from 30mg to 15mg on cardiovascular function and
body weight in 13 patients with SAI. After 3 months there was
no change in body weight (44). Danilowicz et al. successively
demonstrated that the reduction of HC on average by 50% in 11
patients with SAI decreased the body weight by 7 kg while insulin
levels and fasting glucose unchanged (45).
In hypopituitary patients with severe untreated GHD, GC
daily doses are positively correlated with BMI and serum
cholesterol levels. Patients receiving HC equivalent (HCeq)
doses of less than 20 mg/day did not diverge in metabolic
parameters from adrenal sufficient patients. After increasing
HCeq dose, higher BMI, serum lipids were observed. Baseline
serum insulin growth factor I (IGF-I) varied on the basis of the
type and dose of GC therapy, whereas the 1-yr response to GH
treatment in metabolic risk factors was not influenced by GC
regimen (40).
In a large French cohort (79 PAI, 122 SAI), Castinetti et al.
found only a small difference in HC doses between patients
with or with-out dyslipidemia, but not in other metabolic
variables (46). In a German study (194 PAI, 140 SAI), BMI was
not different in groups supplemented by high (>30 mg/day)
or lower doses of HC (47). In other real-life surveys, from
Poland and France, no correlation was found between the daily
dose of HC and fasting glycaemia or insulinemia (46). Slightly
different is the case of SAI, where an apparent relationship
between weight-adjusted HC dose and high blood pressure has
been described, but again not with diabetes mellitus (46, 48).
Recently, a double blind, randomized, crossover trial compared
the effects of 3 dosing regimens in 18 patients with SAI (49).
Subjective improvement was observed with only a twice daily
regimen, namely HC 10mg at 07:00 am and 5mg at 03:00 pm.
Conversely, another Swedish study with 15 patients with PAI
found that a 4-dose regimen was preferred, with higher QOL
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scores (50). However, this regimen resulted in a much higher
cortisol exposure (24 h-cortisol area under the curve), which in
the long-term might be deleterious from a metabolic point of
view (50).
Recently, increased awareness about the detrimental effects of
mild glucocorticoid over treatment in patients with AI has led
to a lower GC daily dose. However, none of these studies found
an inverse association between glucocorticoid exposure and the
incidence of adrenal crises (<12.5 mg/day, 12.5–30 mg/day or
>30 mg/day) (51).
McConnell et al. (52) in a randomized crossover study with
15 patients with SAI, did not find any difference in hepatic and
peripheral insulin sensitivity comparing conventional oral HC
replacement with HC infusions (52).
Several studies have investigated the effects of the new
formulations of GCs focusing on metabolic effects of these
treatments (Table 1). In particular, the od-MRHC treatment has
been demonstrated to have a positive effect on body weight
and glycosilated hemoglobin (HbA1c) in patients with PAI (17,
53). The od-MRHC regimen has been shown to slightly reduce
BMI andHbA1c in a previous parallel open, non-randomized,
prospective trial on a mixed AI population (PAI, SAI and
congenital adrenal hyperplasia) (18).
An open clinical trial evaluated the effects of od-MRHC on
the glycometabolic profile and health-related quality of life of
10 PAI and 9 SAI patients. After 12 months therapy with the
od-MRHC, no changes in fasting glucose, insulin resistance and
BMI were observed in either population while HbA1c levels were
significantly reduced in patients with PAI (54).
In a single-blind randomized active comparator, non-
intervention parallel-group controlled trial, Isidori et al. (19)
demonstrated that a restoration of physiological circadian
glucocorticoid rhythm by replacement of conventional GC
therapy with od-MRHC regimen reduced the body weight of
44 PAI and 45 SAI patients. In particular, at 24 weeks, body
weight reduction was superior in patients in the od-MRHC
group compared with those in the conventional treatment
group (−2.1 kg [95%CI,– 4.0 to −0.3] vs.1.9 kg [– 0.1 to 3.9];
treatment difference – 4.0 kg, 95% CI −6.9 to −1.1; p = 0.008).
Subgroup analysis for type of AI showed greater reductions in
BMI (p = 0.081) and body weight (p = 0.074) in SAI than
PAI patients. Conversely, any change in fasting blood glucose,
insulin and the homoeostatic model assessment (HOMA) index
wasn’t found between the two intervention groups (conventional
treatment/od-MRHC treatment) (19). This suggest that obesity
in SAI can be targeted by improving GC administration.
This is consistent with the demonstration that HC
administration in the evening, compared to a morning
administration, produces a much more pronounced delayed
hyperglycaemic effect with deleterious consequence on
metabolism (55). In 1999, authors hypothesized this effect
could be due to a greater sensitivity to GCs in the evening (55).
An Italian 36-months retrospective study evaluated the effects
of od-MRHC in 13 PAI e 36 SAI patients with normal glucose
tolerance (NGT) and pre-diabetes including impaired fasting
glucose (IFG), and/or impaired glucose tolerance (IGT), on
insulin secretion, and sensitivity, anthropometric parameters
and cardiometabolic risk, indirectly expressed by the visceral
adiposity index (VAI). In patients with AI-NGT and AI-pre-
diabetes a significant decrease in BMI (p= 0.017 and p < 0.001),
waist circumference (p = 0.008 and p < 0.001), HbA1c
(p = 0.034 and p = 0.001) and a significant increase in high-
density lipoprotein cholesterol (p = 0.036 and p = 0.043) were
respectively observed. In addition, in pre-diabetic patients only a
significant decrease in insulinemia (p = 0.014), AUC2h insulinemia
(p = 0.038) and VAI (p = 0.001), in concomitance with
a significant increase in the oral disposition index (DIo;
p = 0.041) and Matsuda index of insulin sensitivity (ISI-
Matsuda; p= 0.038) were observed. No differences in metabolic
parameters, insulin secretion and sensitivity index were found
comparing PAI and SAI patients (56).
CONCLUSION
Secondary adrenal insufficiency has been reportedly associated
with altered glycometabolic profile and increased cardiovascular
risk (57), possibly due to over-replacement. However, a reduction
in glucocorticoid daily dose has not been universally associated
with improved glucose homeostasis, cardiovascular risk and
overall morbidity. Randomized clinical trial addressing this point
are very few.
In fact, specific data on glucose homeostasis alterations
and improvement with different GC regimens in SAI are
scarce and influenced by many confounding factors such as
comorbidities, age, multiple pituitary hormone deficiencies and
other replacement therapies.
In SAI patients with a residual ACTH secretion, the daily
requirement of glucocorticoid might be lower than in PAI.
Nevertheless, in the clinical practice, tailoring of GC replacement
is often suboptimal, and there is a tendency to over-treat patients
with SAI. This could be even more problematic than in PAI
because of their increased metabolic risk.
Recently, the introduction of a new modified release
formulation with a more physiological cortisol circadian profile
has been associated with significant metabolic improvement in
body weight, HbA1c and insulin sensitivity in SAI.
This prompted the hypothesis that a disruption of the
physiological circadian rhythm could have a role in the
observed glicometabolic alterations. Recent finding that patients
with alterations of clock-related genes, such as patients with
sleep disturbances or psychiatric disorders, and as recently
demonstrated patients with AI (58) are exposed to increased
cardiovascular risk andmetabolic syndrome support this concept
(59, 60).
A greater attention toward the dose and timing of
glucocorticoid administration should be placed in patients
with AI, tailoring the overall exposure to the residual HPA
function and circadian rhythm of affected patients in order to
limit their adverse metabolic profile.
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